1. ATRA increases iodine uptake and inhibits the proliferation and invasiveness of human anaplastic thyroid carcinoma SW1736 cells: Involvement of β-catenin phosphorylation inhibition
- Author
-
Hailing Chen, Li-li Deng, Wei Deng, Lili Huo, Ling Lan, Yong Luo, Spyros Basourakos, Xuemei Zuo, Bingyin Shi, Dai Cui, and Guoying Zhang
- Subjects
0301 basic medicine ,all-trans-retinoic acid ,Cancer Research ,biology ,Oncogene ,Cell growth ,Cell ,isotope susceptibility ,anaplastic thyroid carcinoma ,Vimentin ,Articles ,sodium/iodine symporter ,Cell cycle ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,Oncology ,Apoptosis ,Cell culture ,030220 oncology & carcinogenesis ,Catenin ,biology.protein ,medicine ,Cancer research - Abstract
All-trans-retinoic acid (ATRA) can enhance iodine uptake capability of thyroid tumors, but the mechanisms remain poorly understood. The aim of the present study was to investigate the effects of ATRA on isotope susceptibility, proliferation and invasion of anaplastic thyroid carcinoma (ATC) and potential mechanisms. SW1736 cells were treated with 1 µmol/l ATRA or 1% ethanol for 5 days. A cell line stably expressing β-catenin-shRNA was established. An iodine uptake assay was performed using 125I. Proliferation and invasiveness were tested using MTT and Transwell assays, respectively. Western blotting was used to assess the expression of β-catenin, glycogen synthase kinase-3β (GSK-3β), sodium/iodine symporter (NIS) and proteins involved in epithelial-mesenchymal transition. Cells pretreated with ATRA were injected subcutaneously into SCID mice. Mice were intraperitoneally injected with 131I once on the first day of treatment, and tumor growth was then assessed. After 35 days of 131I treatment, ATRA-pretreated tumor volume and weight were decreased compared with the 131I alone group (163.32±19.57 vs. 332.06±21.37 mm3; 0.35±0.14 vs. 0.67±0.23 g, both P
- Published
- 2017